SNAP Trial

Current Staphylococcus aureus bacteraemia (SAB) treatment usually involves prolonged courses of exclusively intravenous (IV) beta lactam antibiotics
Prolonged IV antibiotic treatment is associated with an increased risk of adverse effects, inconvenience for patients, and high cost when compared to oral antibiotics
There is currently no evidence demonstrating superior clinical outcomes with IV administration compared to oral administration.
Current studies suggest that co-administration of oral beta-lactam antibiotics with probenecid (PCT therapy) significantly improves drug exposure in serum
This study aims to demonstrate the aforementioned effect of PCT in SAB infections, along with its potential as a safe and effective alternative to weeks of IV antibiotic therapy.

This substudy is being conducted in New Zealand.

Lead Investigators:

Dr. Max Bloomfield - Te Whatu Ora - Capital, Coast and Hutt Valley, Wellington Hospital (Maxim.Bloomfield@ccdhb.org.nz)

Dr. Genevieve Walls - Te Whatu Ora - Counties Manukau, Middlemore Hospital (Genevieve.Walls@middlemore.co.nz)

Blood samples will be collected during the intravenous and oral phases of each participant's treatment
A convenience sampling method will be used where possible (i.e at the same time of other necessary blood tests that are part of the hospital's standard of care)

Risks:

Blood sample collection involves minimal volume and poses no significant risk to study participants
Antibiotic treatment involves some potential adverse events but are outlined as per SNAP core protocol.

SNAP Proposals

SNAP Trial

SNAPstrat: Patient stratification using SAB sub-phenotypes

Any Interested

Substudy in Progress

Cefazolin Versus Penicillin for Penicillin-Susceptible Staphylococcus aureus Bacteremia: A Secondary Analysis of the SNAP Backbone Trials

Australia, New Zealand, Singapore, Canada, Europe, Israel, South Africa

Substudy in Progress

Significance of S. aureus bacteriuria in patients hospitalized with S. aureus bacteremia

Any Interested

Substudy in Progress

A statistical genomics framework to improve prediction of treatment outcomes of Staphylococcus aureus bacteraemia (SAB)

Australia

Substudy in Progress